Carregant...
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors
EGFR is an oncogene with a high frequency of activating mutations in nonsmall cell lung cancer (NSCLC). EGFR inhibitors have been FDA-approved for NSCLC and have shown efficacy in patients with certain EGFR mutations. However, only 9% to 26% of these patients achieve objective responses. In our stud...
Guardat en:
| Publicat a: | Int J Cancer |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7880578/ https://ncbi.nlm.nih.gov/pubmed/32406930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33053 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|